Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H16F3N3O4 |
| Molecular Weight | 371.3111 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(NN=N1)O[C@H]2CC[C@@H](CC2)C3=CC=C(OC(F)(F)F)C=C3
InChI
InChIKey=UINBFJPVDKLYIY-HOMQSWHASA-N
InChI=1S/C16H16F3N3O4/c17-16(18,19)26-12-7-3-10(4-8-12)9-1-5-11(6-2-9)25-14-13(15(23)24)20-22-21-14/h3-4,7-9,11H,1-2,5-6H2,(H,23,24)(H,20,21,22)/t9-,11-
| Molecular Formula | C16H16F3N3O4 |
| Molecular Weight | 371.3111 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:26:15 GMT 2025
by
admin
on
Wed Apr 02 09:26:15 GMT 2025
|
| Record UNII |
WC82E7HRU5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
882922
Created by
admin on Wed Apr 02 09:26:15 GMT 2025 , Edited by admin on Wed Apr 02 09:26:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2360927-98-4
Created by
admin on Wed Apr 02 09:26:15 GMT 2025 , Edited by admin on Wed Apr 02 09:26:15 GMT 2025
|
PRIMARY | |||
|
WC82E7HRU5
Created by
admin on Wed Apr 02 09:26:15 GMT 2025 , Edited by admin on Wed Apr 02 09:26:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
BMN 255 (also referred to as B209859, BMN255-DS, BMN255, and BMN-255) is an oral, small molecule inhibitor of glycolate oxidase (GO) which will reduce the conversion of glycolate to glyoxylate, the metabolic precursor of oxalate, and thereby decrease urine oxalate excretion. Glycolate oxidase inhibition will also increase plasma glycolate, which is safely excreted in urine
|
![Structure of 5-[[trans-4-[4-(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid](/img/2f2e83ee-3446-482c-bdc4-be7aa10b80ae.svg "Structure of 5-[[trans-4-[4-(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid")